The protein array laboratory is part of the ImmunoLingo convergence center at University of Oslo. With arrays consisting of color-coded microspheres, we work with thousands of antibodies and proteins in parallel. Our technology known as Microsphere Affinity Proteomics (MAP) provides entirely new possibilities for large-scale protein analysis, screening for targets of auto-antibodies and high-throughput assessment of antibody specificity. Since the start of the COVID-19 pandemic, the protein array laboratory has become the key center for monitoring of coronavirus immunity in Norway (see "in the media").
|Fridtjof is a partner in the National network of Advanced Proteomics Infrastructure (NAPI), which comprises researchers from across Norway working in the field of mass spectrometry-based proteomics.
The website to link to is: www.napi.uio.no
Group leader Fridtjof Lund-Johansen, Department of Immunology, Oslo University Hospital, Rikshospitalet, Tel: +47 23073016, E-mail: firstname.lastname@example.org
The goal of our research is to put proteomics into the hands of antibody users.
The analytical power of mass spectrometry (MS) is immense, but it is not realistic to expect that our MS core facilities can be built to handle more than a few samples per day. The large majority of research on proteins is therefore based on detection methods such as western blotting where one or a few proteins are measured in each experiment.
In microsphere affinity proteomics (MAP) antibodies and recombinant proteins are bound to microspheres with thousands of fluorescent bar codes. A flow cytometer is used to read the bar codes and measure fluorescence from sample proteins captured onto the microsphere surface. With MAP technology, scientists can detect thousands of proteins in multiple samples on a daily basis.
Current applications include large-scale detection of protein complexes in subcellular fractions, detection of protein interaction partners and measurement of protein phosphorylation. MAP protein arrays provide means to rapidly identify the targets of auto-antibodies or determine the specificity of antibodies used for research purpose.